

Markus Kosel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/971604/publications.pdf>

Version: 2024-02-01

46
papers

2,584
citations

331670

21
h-index

254184

43
g-index

49
all docs

49
docs citations

49
times ranked

3344
citing authors

#	ARTICLE	IF	CITATIONS
1	Neurodevelopmental Disorders: From Pathophysiology to Novel Therapeutic Approaches. <i>Biomedicines</i> , 2022, 10, 623.	3.2	1
2	The utility of the autism-spectrum quotient to screen for autism spectrum disorder in adults with attention deficit/hyperactivity disorder. <i>Psychiatry Research</i> , 2022, 312, 114580.	3.3	3
3	Cross-cultural preliminary validation of a measure of social vulnerability in people with intellectual disabilities. <i>Journal of Intellectual and Developmental Disability</i> , 2021, 46, 67-79.	1.6	2
4	Prevalence of Polypharmacy and Inappropriate Medication in Adults With Intellectual Disabilities in a Hospital Setting in Switzerland. <i>Frontiers in Psychiatry</i> , 2021, 12, 614825.	2.6	6
5	Pain interventions in adults with intellectual disability: A scoping review and pharmacological considerations. <i>European Journal of Pain</i> , 2020, 24, 875-885.	2.8	8
6	Effect of Ketamine on Rumination in Treatment-Resistant Depressive Patients. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 607-610.	1.4	8
7	TOP-ID: a Delphi technique-guided development of a prescription and deprescription tool for adults with intellectual disabilities. <i>BMJ Open</i> , 2020, 10, e039208.	1.9	0
8	Increased Reactivity of the Mesolimbic Reward System after Ketamine Injection in Patients with Treatment-resistant Major Depressive Disorder. <i>Anesthesiology</i> , 2019, 130, 923-935.	2.5	36
9	Development of inhibitory synaptic inputs on layer 2/3 pyramidal neurons in the rat medial prefrontal cortex. <i>Brain Structure and Function</i> , 2018, 223, 1999-2012.	2.3	14
10	Novel NEXMIF pathogenic variant in a boy with severe autistic features, intellectual disability, and epilepsy, and his mildly affected mother. <i>Journal of Human Genetics</i> , 2018, 63, 847-850.	2.3	15
11	Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 590-597.	1.4	32
12	Predicting Mood Changes in Bipolar Disorder Through Heartbeat Nonlinear Dynamics. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2016, 20, 1034-1043.	6.3	51
13	Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 65, 85-95.	4.8	23
14	Telemonitoring with respect to Mood Disorders and Information and Communication Technologies: Overview and Presentation of the PSYCHE Project. <i>BioMed Research International</i> , 2014, 2014, 1-12.	1.9	22
15	Cognitive Functioning in Patients Remitted from Recurrent Depression: Comparison with Acutely Depressed Patients and Controls and Follow-up of a Mindfulness-Based Cognitive Therapy Trial. <i>Cognitive Therapy and Research</i> , 2013, 37, 1004-1014.	1.9	32
16	Brain stimulation therapies for neuropsychiatric disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 106, 681-695.	1.8	17
17	Salivary cortisol profiles in patients remitted from recurrent depression: One-year follow-up of a mindfulness-based cognitive therapy trial. <i>Journal of Psychiatric Research</i> , 2012, 46, 80-86.	3.1	34
18	Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. <i>Pharmacogenomics</i> , 2011, 12, 365-377.	1.3	49

#	ARTICLE	IF	CITATIONS
19	Pegylated human interferon alpha 2a does not induce depression-associated changes in mice. <i>Psychiatry Research</i> , 2011, 185, 243-247.	3.3	9
20	Chronic vagus nerve stimulation for treatment-resistant depression increases regional cerebral blood flow in the dorsolateral prefrontal cortex. <i>Psychiatry Research - Neuroimaging</i> , 2011, 191, 153-159.	1.8	76
21	Interaction of psychotropic drugs with monoamine oxidase in rat brain. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 53, 1125-1130.	2.4	12
22	Phenomenology of racing and crowded thoughts in mood disorders: A theoretical reappraisal. <i>Journal of Affective Disorders</i> , 2010, 121, 189-198.	4.1	29
23	Current status of brain imaging in anxiety disorders. <i>Current Opinion in Psychiatry</i> , 2009, 22, 96-110.	6.3	136
24	Cerebral blood flow effects of acute intravenous heroin administration. <i>European Neuropsychopharmacology</i> , 2008, 18, 278-285.	0.7	19
25	Deep Brain Stimulation to Reward Circuitry Alleviates Anhedonia in Refractory Major Depression. <i>Neuropsychopharmacology</i> , 2008, 33, 368-377.	5.4	893
26	Pattern of regional cerebral blood-flow changes induced by acute heroin administration – a perfusion MRI study. <i>Journal of Neuroradiology</i> , 2007, 34, 322-329.	1.1	13
27	Mood improvement after deep brain stimulation of the internal globus pallidus for tardive dyskinesia in a patient suffering from major depression. <i>Journal of Psychiatric Research</i> , 2007, 41, 801-803.	3.1	97
28	Repetitive transcranial magnetic stimulation (rTMS) in depression. <i>Poiesis & Praxis</i> , 2006, 4, 111-127.	0.3	2
29	Decreased frontal white-matter volume in chronic substance abuse. <i>International Journal of Neuropsychopharmacology</i> , 2006, 9, 147.	2.1	94
30	Brain Stimulation in Depression. , 2005, , 403-425.		2
31	Diminished GABAA Receptor-Binding Capacity and a DNA Base Substitution in a Patient with Treatment-Resistant Depression and Anxiety. <i>Neuropsychopharmacology</i> , 2004, 29, 347-350.	5.4	14
32	Repetitive transcranial magnetic stimulation: a putative add-on treatment for major depression in elderly patients. <i>Psychiatry Research</i> , 2004, 126, 123-133.	3.3	158
33	Novel physical treatments for major depression: vagus nerve stimulation, transcranial magnetic stimulation and magnetic seizure therapy. <i>Current Opinion in Psychiatry</i> , 2004, 17, 15-20.	6.3	13
34	Beyond the Treatment of Epilepsy: New Applications of Vagus Nerve Stimulation in Psychiatry. <i>CNS Spectrums</i> , 2003, 8, 515-521.	1.2	36
35	Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Affective Disorders. <i>Neuropsychopharmacology</i> , 2003, 28, 201-205.	5.4	58
36	Magnetic Seizure Therapy Improves Mood in Refractory Major Depression. <i>Neuropsychopharmacology</i> , 2003, 28, 2045-2048.	5.4	111

#	ARTICLE	IF	CITATIONS
37	Mechanisms and State of the Art of Vagus Nerve Stimulation. Journal of ECT, 2002, 18, 189-192.	0.6	21
38	Paroxetine Increases Steady-State Concentrations of (R)-Methadone in CYP2D6 Extensive but Not Poor Metabolizers. Journal of Clinical Psychopharmacology, 2002, 22, 211-215.	1.4	81
39	In vitro metabolism of citalopram by monoamine oxidase B in human blood. European Neuropsychopharmacology, 2001, 11, 75-78.	0.7	13
40	Cytochrome P450 2D6 Genotype and Methadone Steady-State Concentrations. Journal of Clinical Psychopharmacology, 2001, 21, 229-234.	1.4	102
41	Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine After Multiple Doses of Fluoxetine in Cytochrome P4502D6 Poor and Extensive Metabolizers. Journal of Clinical Psychopharmacology, 2001, 21, 330-334.	1.4	57
42	Cytochrome P-450 activities in human and rat brain microsomes. Brain Research, 2000, 855, 235-243.	2.2	72
43	Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. International Journal of Neuropsychopharmacology, 2000, 3, 55-60.	2.1	19
44	Pharmacokinetic Consequences of a Citalopram Treatment Discontinuation. Therapeutic Drug Monitoring, 1999, 21, 263.	2.0	9
45	Stereoselective Biotransformation of the Selective Serotonin Reuptake Inhibitor Citalopram and Its Demethylated Metabolites by Monoamine Oxidases in Human Liver. Biochemical Pharmacology, 1998, 56, 15-23.	4.4	83
46	Adaptation Process and Psychometric Properties of the French Version of the Health of the Nation Outcome Scales for People with Learning Disabilities. Journal of Mental Health Research in Intellectual Disabilities, 0, , 1-12.	2.0	1